Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.
Atara Biotherapeutics and its awesome T-cell therapy against Epstein–Barr virus can really cure progressive forms of multiple sclerosis.
Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Siponimod released by Novartis is an improved version of Gilenya.